Get the Stockscreener App
36.08
6.78%
2.29
Pre-market:
36.00
-0.08
-0.22%
Bridgebio Pharma Inc stock is traded at $36.08, with a volume of 3.43M.
It is up +6.78% in the last 24 hours and up +36.20% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$33.79
Open:
$34.01
24h Volume:
3.43M
Relative Volume:
1.58
Market Cap:
$6.82B
Revenue:
$217.77M
Net Income/Loss:
$-438.86M
P/E Ratio:
-14.97
EPS:
-2.41
Net Cash Flow:
$-456.33M
1W Performance:
+1.33%
1M Performance:
+36.20%
6M Performance:
+37.76%
1Y Performance:
-1.53%
1-Day Range:
$34.01
$36.29
1-Week Range:
$33.73
$36.29
52-Week Range:
$21.62
$41.04
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
36.08 | 6.82B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
First Week of March 21st Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
Moss Adams Wealth Advisors LLC Acquires New Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in December - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6%Time to Buy? - MarketBeat
Hypoparathyroidism Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart
Hypoparathyroidism Market Anticipated to Expand Rapidly - openPR
Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers? - MSN
Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength? - MSN
BridgeBio Pharma Is A Buy On Dips After Attruby’s FDA Approval (NASDAQ:BBIO) - Seeking Alpha
Why BridgeBio Pharma (BBIO) Led the Monday Upsurge? - MSN
Epidermolysis Bullosa Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie - The Globe and Mail
BridgeBio Pharma Stock Earns 87 RS Rating - Yahoo! Voices
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 6.6%What's Next? - MarketBeat
BridgeBio reports strong Attruby launch, advances phase 3 trials By Investing.com - Investing.com Australia
BridgeBio Pharma Reports Strong Drug Uptake and Trial Progress - TipRanks
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - Yahoo! Voices
BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseHere's Why - MarketBeat
Investors Purchase High Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO) - MarketBeat
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - Yahoo Finance
BridgeBio trades higher on pipeline progress By Investing.com - Investing.com Nigeria
BridgeBio Pharma in Strong Cash Position to Launch Attruby -January 13, 2025 at 12:02 pm EST - Marketscreener.com
BridgeBio trades higher on pipeline progress - Investing.com
BridgeBio Pharma in Strong Cash Position to Launch Attruby - MarketWatch
BridgeBio reports strong Attruby launch, advances phase 3 trials - Investing.com
BridgeBio's Attruby Gains Momentum with 430 Prescriptions as Three Phase 3 Trials Hit Key Milestone - StockTitan
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing - Simply Wall St
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
BridgeBio Oncology Therapeutics (BBOT) Granted U.S. FDA Fast Track Designation for BBO-8520 for KRAS - Business Wire
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Pharma CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Is This Biotech Stock With 150% Upside a Buy Now? - MSN
Astrazeneca Plc ADR (AZN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Is This Biotech Stock With 150% Upside A Buy Now? - Barchart
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Principal Financial Group Inc. - MarketBeat
BridgeBio price target raised to $50 from $45 at Evercore ISI - Yahoo Finance
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
Bridgebio’s Attruby FDA nod boosts stock; 10 November approvals - BioWorld Online
How To Trade (BBIO) - Stock Traders Daily
BridgeBio Oncology Therapeutics (BBOT) to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - BioSpace
Geode Capital Management LLC Purchases 123,540 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):